Gofen & Glossberg LLC IL increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 480,157 shares of the biopharmaceutical company’s stock after purchasing an additional 3,213 shares during the quarter. Gofen & Glossberg LLC IL’s holdings in Pfizer were worth $17,391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Pennsylvania Trust Co bought a new position in Pfizer in the fourth quarter valued at about $22,749,000. Atria Investments LLC raised its stake in shares of Pfizer by 12.3% in the fourth quarter. Atria Investments LLC now owns 234,610 shares of the biopharmaceutical company’s stock worth $8,498,000 after buying an additional 25,728 shares during the period. Hexavest Inc. raised its stake in shares of Pfizer by 1.9% in the fourth quarter. Hexavest Inc. now owns 6,927,838 shares of the biopharmaceutical company’s stock worth $250,926,000 after buying an additional 129,181 shares during the period. Daiwa SB Investments Ltd. raised its stake in shares of Pfizer by 25.2% in the fourth quarter. Daiwa SB Investments Ltd. now owns 8,540 shares of the biopharmaceutical company’s stock worth $309,000 after buying an additional 1,720 shares during the period. Finally, Acropolis Investment Management LLC raised its stake in shares of Pfizer by 333.4% in the fourth quarter. Acropolis Investment Management LLC now owns 9,032 shares of the biopharmaceutical company’s stock worth $327,000 after buying an additional 6,948 shares during the period. 71.41% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently commented on PFE shares. Morningstar set a $38.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. UBS Group set a $42.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a research note on Wednesday, January 24th. Finally, Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $39.40.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter last year, the business posted $0.47 earnings per share. The firm’s revenue was up .6% on a year-over-year basis. analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were given a dividend of $0.34 per share. The ex-dividend date was Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.71%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 77.71%.
Pfizer declared that its board has authorized a stock repurchase plan on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.
In other Pfizer news, insider Mikael Dolsten sold 69,699 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $36.59, for a total transaction of $2,550,286.41. Following the completion of the transaction, the insider now owns 120,784 shares in the company, valued at approximately $4,419,486.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $36,790. The disclosure for this sale can be found here. Insiders have sold a total of 185,464 shares of company stock valued at $6,767,939 in the last 90 days. 0.06% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Pfizer Inc. (PFE) Shares Bought by Gofen & Glossberg LLC IL” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/03/13/pfizer-inc-pfe-shares-bought-by-gofen-glossberg-llc-il.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.